Zilver PTX Stent Recall Issued Due to Tip Separation Risk

All Zilver PTX drug eluting stents have been recalled due to a faulty delivery system, which may not meet government standards, resulting in at least one patient death and other complaints.  

The Zilver PTX Drug Eluting Stent recall was announced by the FDA on April 24, due to the potential that the delivery system’s tip may separate from the catheter, posing a risk of removal surgery, vascular occlusion, thrombosis, amputation, cardiac arrest, and even death.

At least 13 complaints of problems with Zilver PTX stents have been received by the manufacturer, including at least 2 cases involving inner delivery catheter breakage. At least one of those patients died following the Zilver PTX stent complications.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The recalled Zilver PTX stents are small mesh tubes with an outer drug coating used to help prevent an artery from narrowing. The stents are implanted by a physician by making a small incision in the groin region where the stent is inserted and guides a catheter to the appropriate location in the artery to allow blood flow and prevent common circulatory problems.

The recall includes all sizes, diameters, and lot numbers of Zilver PTX drug eluding stent manufactured by Cook Inc. of Limerick, Ireland from December 13, 2012 through April 16, 2013. The stents were approved for sale in at least 54 countries including the United States, Japan, Australia, and Brazil.

The delivery system tip has been deemed to not meet the established design criteria and is being thoroughly investigated for further issues that may arise from the inner delivery systems and Cook Inc. announced there is a 0.043 occurrence rate that the delivery system tip may separate.

The vice president of Cook Inc. released a statement saying that if patients have had the Zilver PTX drug eluting stent implanted and the delivery system was removed, there is no risk to those patients nor to those with the “bare metal” version of Cook Medical’s Zilver Flex stent.

The FDA announced that consignees should immediately stop using the device, quarantine any remaining inventory and return it to Cook Inc. for credit. Any adverse events or problems arising from the recalled stents should be reported to Cook Medical Customer Relations at (800) 457-4500 or 1-812-339-2235 Monday through Friday between 7:30 a.m. and 5:00 p.m. Eastern time or via email at CustomerrelationsNA@cookmedical.com.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted yesterday)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted 2 days ago)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.